Insmed’s medicine didn’t just reduce exacerbations of a chronic lung disease in a phase 3 trial. The drug blew the primary endpoint out of the water with “very statistically significant” results, according to analysts.

Could the IPO window really be reopening for the summer? The second biotech proposition in May seems to suggest the public markets are regaining their allure.

Innovent’s psoriasis contender to IL-23 drugs like Tremfya and Skyrizi cleared skin and improved the severity of disease in a phase 3 test, setting up the company to seek approval from Chinese regulators.

Arrowhead Pharmaceuticals’ hotly anticipated cholesterol disorder drug lowered key lipoproteins that increase the risk of cardiovascular disease in a phase 2 trial, supporting a late-stage program.

Guardant Health’s blood test designed to help screen the population for hidden cases of colorectal cancer may have taken a step closer to FDA approval.

The FDA is upgrading its safety warnings related to complications from Hologic’s implantable marker for breast cancer procedures, after making an alert to the public earlier this year.

Johnson & Johnson’s radiopharmaceutical spurred “profound and durable” responses, however, four patient deaths in the early-stage trial marred the results.

A novel, non-hormonal reversible contraceptive for men appears to be effective in mice, based on the results of a study sponsored by biological analysis company Promega.

A head-to-head study from Medtronic showed that its minimally invasive approach to reaching tissues in the lung suspected of harboring cancer could be just as effective as the current standard of care biopsy, which requires guiding a needle through the skin and into the chest during a CT scan.

Tango Therapeutics has discarded one of its cancer drugs on the dancefloor after the USP1 inhibitor was linked to reports of liver toxicity in a phase 1 trial.